Clinical Trial Update: Clinical Evaluation of 177Lu-AB-3PRGD2 in Various Solid Tumors With Integrin αvβ3 Positive Expression [Phase 1]

View source ↗

Summary

Phase 1 clinical evaluation of 177Lu-AB-3PRGD2 in various solid tumors with integrin αvβ3 expression. The study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumor

Drugs mentioned

• 177Lu-AB-3PRGD2

Snippet

Sponsor: The First Affiliated Hospital of Xiamen University | Conditions: Refractory Solid Tumor | Phase 1 | Status: RECRUITING